Vanderbilt University Medical Center Nashville, TN
Muhammad Hashim Hayat, MBBS1, Samantha Gross2, Sarah Enslin, PA-C3, Fateeha Furqan, MD4, Raseen Tariq, MD4, Vivek Kaul, MD, FACG3; 1Vanderbilt University Medical Center, Nashville, TN; 2Horace Greeley High School, Chappaqua, NY; 3University of Rochester, Rochester, NY; 4Rochester General Hospital, Rochester, NY
Introduction: Pancreatic cancer is the fourth-leading cause of cancer death in the United States (US). Significant progress has been made in screening, surveillance, diagnosis, and treatment of pancreatic neoplasia over the last several years. We analyzed the epidemiology and mortality trends of pancreatic cancer during this time period. Methods: We examined trends in Pancreatic Cancer incidence and incidence-based mortality stratified by sex and race/ethnicity in the United States using the National Cancer Institute (NCI) Surveillance, Epidemiology, and End Results (SEER) program from 2000 to 2017. Results: The age-sex adjusted incidence of pancreatic cancer rose from 11.64 to 13.03 per 100,000 population in the years 2000 to 2017. When stratified on basis of gender and race, it was seen that the incidence rate for males was higher than females, with highest incidence seen among the African American population (15.46 per 100,000) followed by Caucasians (13.02 per 100,000). US age-adjusted sex-race standardized mortality rates per 100,000 increased from 10.55 in 2000 to 11.10 in 2017. The prevalence of pancreatic cancer on January 1, 2017, was recorded to be 78,969 (50.36% females). On stratification based on age group, 62.3% were >65 years, followed by 29.73% for 50 – 64 years and 7.96% were < 50 years. The five-year survival rate for patients with pancreatic cancer was found to be 10.01% (2011-2016), which improved from 5.3% (2000 – 2005) and was not significantly different when compared among sexes and race. Discussion: The incidence and prevalence of pancreatic cancer has increased from year 2000 to 2017. This may be attributed to an increase in the overall population, increasing longevity, and increased diagnosis. The 5-year survival has almost doubled from the years 2000 to 2011. Understanding these trends may help shape future strategy and efforts as well as resource allocation to fight this lethal disease.
Figure 1: Recent Trends in SEER Relative Survival Rate: Year 2000-2017
Figure 2: SEER Incidence Rates By Age at Diagnosis: Year 2013 - 2017
Figure 3: Recent Trends in SEER Relative Survival Rate by Race/Ethnicity: Year 2000-2017
Disclosures: Muhammad Hashim Hayat indicated no relevant financial relationships. Samantha Gross indicated no relevant financial relationships. Sarah Enslin indicated no relevant financial relationships. Fateeha Furqan indicated no relevant financial relationships. Raseen Tariq indicated no relevant financial relationships. Vivek Kaul indicated no relevant financial relationships.